Perlmutter Cancer Center

If your child has been newly diagnosed with Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy), he/she may qualify to participate in a clinical trial studying different combinations of risk-adapted chemotherapy regimens.  The main goal of the study is to determine if a maintenance regimen containing weekly oral methotrexate at 40 mg/m2/week will result in an improved survival without return of the tumor compared to weekly oral methotrexate at 20 mg/m2/week in the average-risk subset of patients.  The study will also investigate other maintenance regimen and their side effects and compare how well they work in treating younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia.